![]() ![]() Malfunction of the insulin pump or insulin infusion set or insulin degradation can rapidly lead to hyperglycemia and ketoacidosis. Consider dosage reduction or discontinuation of TZD if heart failure occurs. Observe for signs and symptoms of heart failure. If hypersensitivity reactions occur, discontinue APIDRA, treat per standard of care and monitor until symptoms and signs resolve.įluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs) with insulin. Severe life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including APIDRA. Use caution in patients who may be at risk for hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. To avoid medication errors between APIDRA and other insulins, instruct patients to always check the insulin label before each injection.Īll insulin products, including Apidra, can cause hypokalemia. Hypoglycemia is the most common adverse reaction associated with insulins, including Apidra, and maybe life-threatening. Advise patients to rotate injection site to unaffected areas and closely monitor for hypoglycemia. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis may result in hyperglycemia sudden change in the injection site (to unaffected area) has been reported to result in hypoglycemia. Dosing should be individualized based on patient characteristics and lifestyle. Changes in insulin regimen including, strength, manufacturer, type, injection site or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment. Modify insulin regimens only under medical supervision. Monitor blood glucose in all patients treated with insulin. Insulin pens and needles must never be shared between patients, even if the needle is changed. Learn more about Insulins Val you Savings ProgramĪpidra is contraindicated during episodes of hypoglycemia and in patients hypersensitive to Apidra or any of its excipients. This offer is not valid for the SOLIQUA 100/33 (insulin glargine and lixisenatide injection) 100 Units/mL and 33 mcg/mL. Upon registration, patients will receive all program details. Sanofi reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms of use at any time without notice. There are other relevant costs associated with overall treatment. The Insulins Val you Savings Program applies to the cost of medication. Patients must fill all their Sanofi Insulin prescriptions at the same time, together each month. Sanofi insulins included in this program are: ADMELOG® (insulin lispro injection) 100 Units/mL, TOUJEO® SoloStar® (insulin glargine injection) 300 Units/mL, TOUJEO® Max SoloStar® (insulin glargine injection) 300 Units/mL, LANTUS® (insulin glargine injection) 100 Units/mL, INSULIN GLARGINE injection 100 Units/mL (U-100) and APIDRA® (insulin glulisine injection) 100 Units/mL Your patients pay $35 per 30 Day Supply of any one or combination of Sanofi Insulins*. ![]() You are encouraged to report negative side effects of prescription drugs to the FDA.If your patients don't have prescription medication insurance they can use Call your doctor for medical advice about side effects. These are not all of the possible side effects of INGREZZA. Other side effects include changes in balance (balance problems, dizziness) or an increased risk of falls, headache, feelings of restlessness, dry mouth, constipation, and blurred vision. The most common side effect of INGREZZA is sleepiness (somnolence). Including prescription and over-the-counter medicines, vitamins, and herbal supplements. Tell your healthcare provider about all the medicines you take, ![]() Symptoms include: shaking, body stiffness, trouble moving or walking, or keeping your balance.īefore taking INGREZZA, tell your healthcare provider about all of your medical conditions including if you: have liver or heart problems, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. Tell your healthcare provider right away if you have a change in your heartbeat (a fast or irregular heartbeat), or if you faint.Symptoms of QT prolongation may include:.INGREZZA may cause a heart problem known as QT prolongation. Heart rhythm problems (QT prolongation).Do not drive, operate heavy machinery, or do other dangerous activities until you know how INGREZZA affects you. INGREZZA may cause serious side effects, including: Are allergic to valbenazine, or any of the ingredients in INGREZZA. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |